Pro Medicus, Limited
ASX: PME
A breakout FY25 powered by soaring U.S. demand and major cloud wins.
(Source: TradingView) 3-Month Performance Profile of PME on a DTF compared to S&P/ASX 200 (XJO).
Pro Medicus closed FY25 with one of its strongest performances to date, due to accelerating demand for its imaging solutions and a rapidly expanding U.S. presence. EBITDA reached $164.93 million,
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
